Description
OLMEROOT-CL 40
Olmesartan Medoxomil 40 mg and Cilnidipine 10 mg Tablets
Division: DIABGLYM
Composition
Each tablet contains:
Olmesartan Medoxomil IP — 40 mg
Cilnidipine IP — 10 mg
Excipients — q.s.
Colour: Approved colour used
Dosage form: Oral tablet
Product Description
OLMEROOT-CL 40 is a scientifically balanced antihypertensive combination of Olmesartan Medoxomil 40 mg and Cilnidipine 10 mg, formulated for the effective management of hypertension and long-term cardiovascular and renal protection. This combination provides dual blood pressure control by combining the renin-angiotensin system blockade of Olmesartan with the advanced dual calcium channel blocking action of Cilnidipine, resulting in superior antihypertensive efficacy and enhanced target organ protection.
Olmesartan Medoxomil is a potent angiotensin II receptor blocker (ARB) that promotes vasodilation, reduces peripheral vascular resistance, and provides cardiovascular and renal protection. Cilnidipine is a unique dual L-type and N-type calcium channel blocker that reduces peripheral vascular resistance, suppresses sympathetic overactivity, improves renal hemodynamics, and minimizes reflex tachycardia.
OLMEROOT-CL 40 is particularly beneficial in patients with uncontrolled hypertension, hypertension associated with diabetes, chronic kidney disease, proteinuria, metabolic syndrome, elderly hypertension, and patients requiring intensive combination antihypertensive therapy.
Technical Knowledge of Olmesartan Medoxomil and Cilnidipine
Olmesartan Medoxomil is a prodrug that is converted to Olmesartan, which selectively blocks angiotensin II type 1 (AT1) receptors, preventing vasoconstriction, aldosterone secretion, sympathetic activation, and vascular remodeling.
Cilnidipine blocks both L-type calcium channels in vascular smooth muscle and N-type calcium channels in sympathetic nerve terminals. This dual mechanism reduces arterial vasoconstriction while decreasing sympathetic neurotransmitter release, resulting in sustained blood pressure reduction, improved renal perfusion, and reduced glomerular hypertension.
The combination of Olmesartan and Cilnidipine provides complementary antihypertensive mechanisms with additional cardiovascular and nephroprotective benefits.
Mechanism of Action
Olmesartan blocks AT1 receptors, promotes vasodilation, reduces peripheral vascular resistance, decreases aldosterone secretion, improves vascular function, and protects cardiovascular and renal tissues.
Cilnidipine blocks L-type and N-type calcium channels, relaxes vascular smooth muscle, suppresses sympathetic activity, improves renal blood flow, reduces glomerular pressure, and provides sustained antihypertensive action.
Key Benefits
Effective reduction of systolic and diastolic blood pressure
Dual antihypertensive mechanism
Provides sustained 24-hour blood pressure control
Supports cardiovascular and renal protection
Reduces sympathetic overactivity
Improves renal hemodynamics
Helps reduce proteinuria in diabetic and renal patients
Minimizes reflex tachycardia
Suitable for long-term hypertension management under medical supervision
Clinical Applications
OLMEROOT-CL 40 is commonly prescribed for essential hypertension, uncontrolled hypertension requiring combination therapy, hypertension with diabetes mellitus, hypertension with chronic kidney disease, hypertension with proteinuria, metabolic syndrome, elderly hypertension, and long-term cardiovascular and renal risk reduction.
Facts About Olmesartan Medoxomil and Cilnidipine
Olmesartan is a highly selective ARB with excellent antihypertensive efficacy and proven cardiovascular and renal protective benefits. Cilnidipine is an advanced calcium channel blocker with dual L-type and N-type channel blocking properties, providing effective blood pressure control with favorable renal and sympathetic modulation effects. The combination is widely used for patients requiring intensive blood pressure control and enhanced nephroprotection.
Key Facts
ARB and dual calcium channel blocker combination therapy
Olmesartan Medoxomil 40 mg for vascular and renal protection
Cilnidipine 10 mg for advanced blood pressure and renal control
Provides sustained 24-hour antihypertensive action
Effective in hypertension with diabetes and chronic kidney disease
Evidence-based cardiovascular and nephroprotective combination therapy
Quality-assured pharmaceutical formulation
PCD Pharma Franchise Opportunity
OLMEROOT-CL 40 is an excellent product for PCD Pharma Franchise, Cardiology Franchise, Nephrology Franchise, and Cardio-Diabetic Franchise across India. The increasing prevalence of hypertension, diabetes, chronic kidney disease, obesity, and cardiovascular disorders creates strong prescription demand and long-term market potential for this combination.
Why Choose OLMEROOT-CL 40 for PCD Pharma Franchise?
High prescription potential
Strong physician and cardiologist acceptance
Attractive monopoly franchise opportunity
Competitive pricing
Promotional support available
Visual aids and marketing inputs
Consistent product quality
Excellent repeat business potential
Third Party Manufacturing
Chemsroot Pharmaceutical offers Third Party Manufacturing of Olmesartan Medoxomil 40 mg and Cilnidipine 10 mg Tablets with complete manufacturing support for pharmaceutical companies, marketers, exporters, and franchise businesses.
Our Third Party Manufacturing Services Include
Private label manufacturing
Contract manufacturing
Custom brand manufacturing
Loan license manufacturing
DCGI-compliant production
GMP-certified manufacturing
Batch manufacturing documentation
Product registration support
Customized packaging and artwork
Monopoly franchise packaging
Bulk manufacturing capability
Manufacturing Features
Pharmaceutical-grade raw materials
IP/BP/USP quality standards
In-process quality control
Finished product testing
Stability-oriented formulation
Moisture-controlled tablet manufacturing
Blister and Alu-Alu packaging options
OLMEROOT-CL 40 from DIABGLYM combines effective blood pressure control, comprehensive cardiovascular and renal protection, evidence-based combination therapy, and high-quality pharmaceutical manufacturing, making it an ideal product for physicians, cardiologists, nephrologists, diabetologists, PCD Pharma Franchise partners, and Third Party Manufacturing clients seeking a reliable Olmesartan and Cilnidipine formulation.